INVO Fertility (NASDAQ:IVF) Posts Quarterly Earnings Results

INVO Fertility (NASDAQ:IVF) announced its earnings results on Friday. The company reported $0.35 earnings per share for the quarter, Zacks reports. INVO Fertility had a negative return on equity of 420.62% and a negative net margin of 183.75%.

INVO Fertility Price Performance

Shares of INVO Fertility stock opened at $0.97 on Friday. The company has a quick ratio of 0.87, a current ratio of 0.90 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $2.23 million, a price-to-earnings ratio of -0.00 and a beta of 2.32. INVO Fertility has a twelve month low of $0.90 and a twelve month high of $84.40. The company has a 50-day simple moving average of $1.27 and a two-hundred day simple moving average of $2.61.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, INVO Fertility presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC purchased a new stake in INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility at the end of the most recent quarter. Institutional investors and hedge funds own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.